Search
- May 9
Attovia Therapeutics raised a $105M series B today to take on the I&I space, including designing multi-target bispecifics
Founder & CEO Tao Fu walks us through the company's ATTOBODY platform and discusses programs targeting IL31 and IL31 x IL13.